NasdaqGS - Nasdaq Real Time Price • USD
Myriad Genetics, Inc. (MYGN)
At close: April 25 at 4:00 PM EDT
After hours: April 25 at 4:20 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 12 | 11 | 12 | 13 |
| Avg. Estimate | -0.1 | 0 | 0.02 | 0.23 |
| Low Estimate | -0.18 | -0.01 | 0 | 0.03 |
| High Estimate | -0.03 | 0.04 | 0.04 | 0.37 |
| Year Ago EPS | -0.21 | -0.08 | -0.27 | 0.02 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 12 | 12 | 13 | 13 |
| Avg. Estimate | 193.51M | 203.97M | 826.58M | 893.79M |
| Low Estimate | 190.36M | 198.5M | 810.15M | 860.19M |
| High Estimate | 196.32M | 210.5M | 832M | 914.32M |
| Year Ago Sales | 181.2M | -- | 753.2M | 826.58M |
| Sales Growth (year/est) | 6.80% | -- | 9.70% | 8.10% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.19 | -0.08 | -0.08 | 0.01 |
| EPS Actual | -0.21 | -0.08 | -0.03 | 0.04 |
| Difference | -0.02 | 0 | 0.05 | 0.03 |
| Surprise % | -10.50% | 0.00% | 62.50% | 300.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.1 | 0 | 0.02 | 0.23 |
| 7 Days Ago | -0.1 | 0 | 0.02 | 0.23 |
| 30 Days Ago | -0.1 | 0 | 0.02 | 0.24 |
| 60 Days Ago | -0.04 | 0 | -0.01 | 0.28 |
| 90 Days Ago | -0.04 | 0 | 0 | 0.29 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 1 | 1 |
| Up Last 30 Days | -- | 1 | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | -- | -- | 1 |
Growth Estimates
| CURRENCY IN USD | MYGN | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 52.40% | -- | -- | 2.60% |
| Next Qtr. | 100.00% | -- | -- | 13.40% |
| Current Year | 107.40% | -- | -- | 5.20% |
| Next Year | 1,050.00% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -8.20% | -- | -- | 11.11% |
| Past 5 Years (per annum) | -37.87% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Goldman Sachs: Buy to Buy | 1/30/2024 |
| Maintains | Goldman Sachs: Buy to Buy | 1/29/2024 |
| Initiated | Piper Sandler: Neutral | 12/21/2023 |
| Initiated | Wells Fargo: Equal-Weight | 12/19/2023 |
| Initiated | Guggenheim: Buy | 12/14/2023 |
| Initiated | Wolfe Research: Outperform | 12/13/2023 |
Related Tickers
VCYT Veracyte, Inc.
19.48
-2.11%
NEO NeoGenomics, Inc.
13.85
-1.28%
QIA.DE Qiagen N.V.
37.94
-1.65%
CDNA CareDx, Inc
7.56
-5.26%
QGEN Qiagen N.V.
41.08
-1.06%
NTRA Natera, Inc.
91.28
-0.24%
RVTY Revvity, Inc.
102.09
-0.57%
SHC Sotera Health Company
11.32
+0.44%
RDNT RadNet, Inc.
48.85
+0.37%
NEOG Neogen Corporation
11.96
-3.31%